

References

M-52

1. Singh V, Kumari G, Chhajjer B, et al. Effectiveness of enhanced external counter pulsation on clinical profile and health-related quality of life in patients with coronary heart disease: A systematic review. *Acta Angiologica*. 2018;24(4):105-22.
2. Raeissadat SA, Javadi A, Allameh F. Enhanced external counterpulsation in rehabilitation of erectile dysfunction: a narrative literature review. *Vasc Health Risk Manag*. 2018;14:393-399.
3. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused update of the 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the heart failure Society of America. *Circ*. 2017;136(6):e137-e161.
4. US Food and Drug Administration (FDA). Cardiomedics, Inc. cardiassist counter pulsation system-series 4000. 510(k) summary. [FDA Web site]. 03/31/2005.
5. US Food and Drug Administration (FDA). Enhanced external counterpulsation MC-2. 510(k) summary. [FDA Web site]. 06/14/2002.
6. Xu L, Chen X, Cui M, et al. The improvement of the shear stress and oscillatory shear index of coronary arteries during enhanced external counterpulsation in patients with coronary heart disease. *PLoS One*. 2020;15(3):e0230144. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082042/pdf/pone.0230144.pdf2>
7. Buschmann EE, Hillmeister P, Bondke Persson A, et al. Short-term external counterpulsation augments cerebral blood flow and tissue oxygenation in chronic cerebrovascular occlusive disease. *Eur J Neurol*. 2018;25(11):1326-1332.